On Monday 3rd April, at the 107th American Association for Cancer Research (AACR) annual meeting in Washington, DC, USA, there was an enthralling poster session focused on the “Molecular Classification of Tumors”.
Anna Ferrari from the Institute of Hematology, Bologna, Italy, and colleagues presented data from their study which investigated the frequency, types, and prognostic impact of TP53 mutations in adult Acute Myeloid Leukemia (AML) patients.
258 adult AML patients with miscellaneous cytogenetic abnormalities and Normal Karyotype (NK-AML, n = 65) were examined for TP53 mutations.
The key results were:
- Using mutation analysis, forty-eight different types of TP53 mutations (deleterious point mutations) were detected in thirty-nine patients
- TP53 mutation rate in patients was 15.1%
- Complex Karyotype (CK) reported in 71.8% of TP53 mutated patients (28/39) compared to 28.2% of TP53 mutated patients (11/39) with no CK; P > 0.0001
- TP53 alterations were significantly associated with poor Overall Survival (OS) and Event Free Survival (EFS); P < 0.0001
- Using Copy Number Analysis (CNA), 44% of TP53 mutations were observed to have concomitant deletion
- OS was not significantly lower in TP53 mutations compared to patients with mutations/deletions; P = 0.77
- Chromosomes were significantly altered in TP53 mutated patients compared to Wild-type (WT) TP53 patients
In conclusion, TP53 mutations are deleterious and significantly correlate with poor prognosis. The authors concluded by suggesting that TP53 mutations and deletion screening should be recommended for AML patients.